PCV90 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS SIMVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK—A SWEDISH ECONOMIC EVALUATION BASED UPON THE JUPITER TRIAL

✍ Scribed by AG Olsson; MM Jensen; SK Gandhi; L Smolen; T Paulsson

• Book ID: 118614626
• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 77 KB
• Volume: 13
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/s1098-3015(11)72432-9